@article{ece3f006226e402faa97eba941fd4189,
title = "An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study",
author = "Ashleigh McGirr and Tara Bourgoin and Michael Wortzman and Brad Millson and McNeil, {Shelly A.}",
note = "Funding Information: Business & Decision Life Sciences platform provided editorial assistance and publications coordination on behalf of GSK. Amrita Ostawal (Arete Communication UG, Germany, on behalf of GSK) provided writing support and Lyes Derouiche coordinated publication development and editorial support related to this manuscript. Josephine Ocran-Appiah (GSK, USA) reviewed the manuscript and provided insights during the development of the manuscript. Ashleigh McGirr is the coordinating investigator and participated in the study design, data analysis, interpretation and writing the outline of the initial draft. All authors participated in the design or implementation or analysis, interpretation of the study; and the development of this manuscript. All authors had full access to the original data and the study report and gave their final approval on the submission version. Early public disclosure of results at the Canadian Immunization Research Network AGM with an abstract and a poster. The CIRN Annual Meeting, 20 & 21 November 2019 - Toronto, Canada. Shingrix is a trademark owned by or licensed to the GSK group of companies. Zostavax is a trademark owned by or licensed to MERCK SHARP & DOHME CORP. Publisher Copyright: {\textcopyright} 2021 GlaxoSmithKline Biologicals SA",
year = "2021",
month = jun,
day = "8",
doi = "10.1016/j.vaccine.2021.04.053",
language = "English",
volume = "39",
pages = "3397--3403",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "25",
}
